Literature DB >> 28567539

Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.

Josefine Britze1, Gorm Pihl-Jensen1, Jette Lautrup Frederiksen2.   

Abstract

The aim of this study was to summarise existing findings regarding optical coherence tomography (OCT) measurements of ganglion cell layer (GCL) alterations in optic neuritis (ON) and multiple sclerosis (MS). Peer-reviewed studies published prior to April 2016 were searched using PubMed, EMBASE, Web of Science and Scopus. Studies were included if they measured GCL thickness using OCT in patients with either ON, MS or clinically isolated syndrome. For the meta-analysis, we compared GCL thickness in MS patients with and without prior ON, to healthy controls. 42/252 studies were reviewed. In acute ON, studies showed significant thinning of the GCL within the first 5 weeks (n = 5), earlier than retinal nerve fibre layer (RNFL) thinning. GCL thinning at 1-2 months after acute ON predicted visual function at 6 months (n = 3). The meta-analysis showed that the thickness of the GCL was significantly reduced in MS patients both with and without previous ON compared to healthy controls. GCL thinning was associated with visual function in most studies (n = 10) and expanded disability status scale (EDSS) scores (n = 6). In acute ON, thinning of the GCL is measurable prior to RNFL thinning, and GCL thickness after 1-2 months may predict visual function after 6 months. Furthermore, GCL thinning occurs in MS both with and without prior ON, and may be associated with visual function and EDSS score. This suggests that the GCL is a promising biomarker, which may be used to examine in vivo neurodegeneration in ON and MS.

Entities:  

Keywords:  Multiple sclerosis; Optic nerve; Optic neuritis; Optical coherence tomography; Retina

Mesh:

Year:  2017        PMID: 28567539     DOI: 10.1007/s00415-017-8531-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  61 in total

1.  Disease course heterogeneity and OCT in multiple sclerosis.

Authors:  L J Balk; P Tewarie; J Killestein; C H Polman; Bmj Uitdehaag; A Petzold
Journal:  Mult Scler       Date:  2014-01-08       Impact factor: 6.312

2.  A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis.

Authors:  Olivier Outteryck; Bilal Majed; Sabine Defoort-Dhellemmes; Patrick Vermersch; Hélène Zéphir
Journal:  Mult Scler       Date:  2015-03-31       Impact factor: 6.312

3.  Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Authors:  L J Balk; M D Steenwijk; P Tewarie; M Daams; J Killestein; M P Wattjes; H Vrenken; F Barkhof; C H Polman; B M J Uitdehaag; A Petzold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-27       Impact factor: 10.154

4.  Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.

Authors:  Shiv Saidha; Stephanie B Syc; Mary K Durbin; Christopher Eckstein; Jonathan D Oakley; Scott A Meyer; Amy Conger; Teresa C Frohman; Scott Newsome; John N Ratchford; Elliot M Frohman; Peter A Calabresi
Journal:  Mult Scler       Date:  2011-08-24       Impact factor: 6.312

5.  Ganglion cell analysis in acute optic neuritis.

Authors:  R Behbehani; A Al-Moosa; D Sriraman; R Alroughani
Journal:  Mult Scler Relat Disord       Date:  2015-10-31       Impact factor: 4.339

6.  Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments.

Authors:  Ute E K Wolf-Schnurrbusch; Lala Ceklic; Christian K Brinkmann; Milko E Iliev; Manuel Frey; Simon P Rothenbuehler; Volker Enzmann; Sebastian Wolf
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

7.  Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study.

Authors:  Shiv Saidha; Elias S Sotirchos; Mohamed A Ibrahim; Ciprian M Crainiceanu; Jeffrey M Gelfand; Yasir J Sepah; John N Ratchford; Jiwon Oh; Michaela A Seigo; Scott D Newsome; Laura J Balcer; Elliot M Frohman; Ari J Green; Quan D Nguyen; Peter A Calabresi
Journal:  Lancet Neurol       Date:  2012-10-04       Impact factor: 44.182

8.  Optical Coherence Tomography for the Detection of Remote Optic Neuritis in Multiple Sclerosis.

Authors:  Lucy T Xu; Robert A Bermel; Amy S Nowacki; Peter K Kaiser
Journal:  J Neuroimaging       Date:  2016-01-15       Impact factor: 2.486

9.  In vivo evaluation of retinal neurodegeneration in patients with multiple sclerosis.

Authors:  Erika Tátrai; Magdolna Simó; Anna Iljicsov; János Németh; Delia Cabrera Debuc; Gábor Márk Somfai
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

10.  Benign Multiple Sclerosis is Associated with Reduced Thinning of the Retinal Nerve Fiber and Ganglion Cell Layers in Non-Optic-Neuritis Eyes.

Authors:  Yu Min Huang-Link; Mats Fredrikson; Hans Link
Journal:  J Clin Neurol       Date:  2015-05-28       Impact factor: 3.077

View more
  26 in total

Review 1.  Optical coherence tomography in multiple sclerosis.

Authors:  Josefine Britze; Jette Lautrup Frederiksen
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

Review 2.  Retinal nerve fiber layer changes in migraine: a systematic review and meta-analysis.

Authors:  HongJie Zhang; PanWen Zhao; PingLei Pan; XiaoGuang Lin; ZhongQuan Yi; XueLing Zhang; QinQin Liu; Hui Zhang; RuYuan Cai; ChaoChun Chen
Journal:  Neurol Sci       Date:  2021-01-13       Impact factor: 3.307

3.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

Review 4.  Can Optical Coherence Tomography Be Used to Guide Treatment Decisions in Adult or Pediatric Multiple Sclerosis?

Authors:  Jeffrey Lambe; Olwen C Murphy; Shiv Saidha
Journal:  Curr Treat Options Neurol       Date:  2018-03-21       Impact factor: 3.598

Review 5.  Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.

Authors:  Hiroshi Komatsu; Goh Onoguchi; Stefan Jerotic; Nobuhisa Kanahara; Yoshihisa Kakuto; Takashi Ono; Shunichi Funakoshi; Takeshi Yabana; Toru Nakazawa; Hiroaki Tomita
Journal:  Mol Psychiatry       Date:  2022-05-02       Impact factor: 15.992

Review 6.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

7.  Functional-structural assessment of the optic pathways in patients with optic neuritis.

Authors:  Mathias Falck Schmidt; Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  Doc Ophthalmol       Date:  2019-10-17       Impact factor: 2.379

Review 8.  Visual Dysfunction in Multiple Sclerosis and its Animal Model, Experimental Autoimmune Encephalomyelitis: a Review.

Authors:  Taekyun Shin; Meejung Ahn; Jeongtae Kim; Kyungsook Jung; Changjong Moon; Moon-Doo Kim
Journal:  Mol Neurobiol       Date:  2021-03-20       Impact factor: 5.590

Review 9.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

Authors:  Frederike C Oertel; Hanna Zimmermann; Friedemann Paul; Alexander U Brandt
Journal:  EPMA J       Date:  2017-12-22       Impact factor: 6.543

10.  Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis.

Authors:  Gabriel Bsteh; Harald Hegen; Patrick Altmann; Michael Auer; Klaus Berek; Franziska Di Pauli; Fritz Leutmezer; Paulus Rommer; Sebastian Wurth; Anne Zinganell; Tobias Zrzavy; Florian Deisenhammer; Thomas Berger
Journal:  Eur J Neurol       Date:  2021-04-02       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.